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The e4 allele of the apolipoprotein E (APOE) gene is currently the strongest
and most highly replicated genetic factor for risk and age of onset of late-
onset Alzheimer’s disease (LOAD). Using phylogenetic analysis, we have
identified a polymorphic poly-T variant, rs10524523, in the translocase of
outer mitochondrial membrane 40 homolog (TOMM40) gene that provides
greatly increased precision in the estimation of age of LOAD onset for APOE
e3 carriers. In two independent clinical cohorts, longer lengths of
rs10524523 are associated with a higher risk for LOAD. For APOE e3/4
patients who developed LOAD after 60 years of age, individuals with long
poly-T repeats linked to APOE e3 develop LOAD on an average of 7 years
earlier than individuals with shorter poly-T repeats linked to APOE e3
(70.5±1.2 years versus 77.6±2.1 years, P¼0.02, n¼34). Independent
mutation events at rs10524523 that occurred during Caucasian evolution
have given rise to multiple categories of poly-T length variants at this locus.
On replication, these results will have clinical utility for predictive risk
estimates for LOAD and for enabling clinical disease prevention studies. In
addition, these results show the effective use of a phylogenetic approach for
analysis of haplotypes of polymorphisms, including structural polymor-
phisms, which contribute to complex diseases.
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Introduction
The prevalence of Alzheimer’s disease (AD) is predicted to quadruple worldwide
by the year 2050 to 4107 million cases, meaning that 1 in 85 persons will be
living with the disease at that time. It has been estimated that delaying AD onset
by 1 or 2 years could decrease the disease burden in 2050 by 9.5 million or
23 million cases, respectively.
1 Late-onset AD (LOAD), which develops after
60–65 years of age,
2,3 is the most common form of the disease, accounting for
over 95% of cases.
3
In all, 58–79% of the predisposition to LOAD is due to genetic factors.
4
Evidence gathered over the past 17 years clearly shows that apolipoprotein E
(APOE) e4 is the strongest and most highly replicated genetic risk factor for LOAD
and is associated with lower age of clinical disease onset.
5,6 The early APOE
discovery was based on modest human linkage data,
7 but has been followed by
robust association of APOE genotypes with diagnosed LOAD and age of onset of
onset distributions.
5 Several genome-wide association screens (GWAS)
6,8–15 and
fine-mapping studies
16–18 have confirmed the association of a region of linkage
disequilibrium (LD) that encompasses three genes, APOE, translocase of outer
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APOC1, with LOAD. However, despite the availability of
whole genome single-nucleotide polymorphism (SNP) tools,
no other common polymorphisms have shown similar
robust and dramatic statistical associations with LOAD.
The rationale for the development of GWAS was to locate
regions of the genome that may harbor specific disease-
associated loci.
16,19 Recently, the emphasis has been on
testing for association between SNPs that are represented on
the available screening tools with a phenotype. This has
introduced the statistical problem of correcting for the large
numbers of SNPs assayed. A statistically significant associa-
tion between an SNP and a phenotype tacitly grants priority
to the SNP, when in fact the SNP is generally present on the
commercial screening product only because it occurs at high
frequency in some population and tags a region of LD. Even
the most ardent enthusiasts for GWAS technology have been
surprised and disappointed by the lack of robust disease-
specific results, leading to calls for analyses of combined
series of tens of thousands of patients and controls.
20
We approached the LD region that includes APOE and
TOMM40 by deep sequencing to catalog all the polymor-
phisms, including structural polymorphisms in addition to
SNPs, and then applying phylogenetics to define the
evolutionary relatedness of the polymorphisms. This tech-
nique is used extensively for evolutionary analyses, from the
evolution of species to the changes occurring in influenza
virus each year. Phylogenetics has been used less frequently
for human disease genetics, but is ideally suited for analysis
of regions of the genome where there is high sequence
diversity and low levels of recombination. Phylogenetic
analysis is fundamentally different from GWAS in that it is
not searching for disease-associated chunks of DNA that
represent LD regions, but rather it identifies collections of
related haplotypes with common ancestral history, that is
clades, that may be enriched for disease-causing variants.
Preliminary genome-wide screens are, therefore, valuable for
flagging linkage regions of potential interest for a particular
phenotype. Using a phylogenetic analysis of a previously
flagged genomic region,
16 we have discovered a poly-
morphic poly-T variant in TOMM40 that is linked to APOE.
The length of this polymorphic poly-Tcontributes to the age
of onset distributions formerly attributed to APOE genotypes
alone by making APOE e3-containing strands more informative.
Mitochondrial dysfunction is an early defect in LOAD
pathogenesis
21–27 and is linked to neuronal cell death.
28
One candidate gene for mitochondrial dysfunction in LOAD
is TOMM40. This gene encodes Tom40, the translocase of
the outer mitochondrial membrane pore subunit, through
which cytoplasmic peptides and proteins pass during
mitochondrial biogenesis.
29 Amyloid precursor protein has
been shown to accumulate in the mitochondrial import
pores, which results in mitochondrial dysfunction in
LOAD.
30,31 In addition, mitochondrial dysfunction and
neurotoxic effects of naturally occurring, neuron-specific
apoE4 1-272 N-terminal peptide fragments interacting at the
outer mitochondrial membrane have also been described.
28
The 30 and 50 ends of the TOMM40 and APOE genes,
respectively, are separated by only B2kb on chromosome 19.
The TOMM40 and APOE genes are in high LD,
17,18 which
may obscure disease risk associated with other APOE
e4-independent variants in the region.
Phylogenetic analysis has been used previously to identify
genomic relationships between low-frequency genetic var-
iants and to cluster evolutionarily related haplotypes.
32 In
this study this methodology is used to explore the TOMM40-
APOE LD block for the existence of novel risk determinants
for LOAD.
Materials and methods
Subjects
The two cohorts analyzed in this study were from the
Arizona Alzheimer’s Disease Research Center, Phoenix,
Arizona, and the Duke Bryan Alzheimer’s Disease Research
Center, Durham, North Carolina. Details of the Exploratory
Study cohort are given in Li et al.
6 All subjects were of
European descent. The Arizona and Duke studies were
approved by the institutional review boards and appropriate
informed consent was obtained from all participants. Age
and gender data for the cases and controls in each cohort are
shown in Table 1. For the Duke cohort, the age of disease
onset was determined retrospectively and disease diagnosis
was confirmed by autopsy for subjects who have died.
DNA samples
For the Exploratory study (ES) and Arizona study (AS)
cohorts, DNA was extracted from blood. For the Duke study
(DS) cohort, DNA was extracted from the blood (for 22
subjects) or brain (for 12 subjects). There was no systematic
bias for the tissue of origin of the DNA in the final analysis
of the DS cohort, that is, long and short rs10524523 alleles
were found in DNA from both tissues. Samples were plated
on 96-well plates for long-range PCR and DNA sequencing at
Polymorphic DNA Technologies (Alameda, CA, USA).
Long-range PCR
Long-range PCR was performed using Takara LA Taq
Polymerase (Takara Mirus Bio, Inc., Madison, WI, USA).
The reaction mix and PCR conditions were the same as those
recommended by the manufacturer. PCR was conducted in
Table 1 Cohort compositions
Series n Mean age (s.d.) Females (%)
Cases Controls Cases Controls Cases Controls
ES 83 67 72.0 (0.9) 74.6 (3.3) 60.2 59.7
AS 74 31 81.7 (8.0) 77.0 (8.9) 56.3 46.7
DS 34 33 69.3 (8.3) 71.9 (7.5) 70.0 66.7
Abbreviations: AS, Arizona study; DS, Duke study; ES, Exploratory study.
The number of cases and controls, mean age and percentage that are female are
shown for each series. Mean age is given as age-at-diagnosis of Alzheimer’s
disease for cases and age-at-examination for controls. The s.d. from the mean is
given in parenthesis.
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genomic DNA. Thermocycling was carried out with the
following conditions: 941C, 1min for 1 cycle; 941C, 30s;
571C, 30s; 681C, 9min for 14 cycles; 941C, 30s; 571C,
30s; 681C, 9minþ15s per cycle for 16 cycles; 721C, 10min
for 1 cycle. Primers for long-range PCR are shown in
Supplementary Table S1.
Large-fragment cloning
PCR products were run on a 0.8% agarose gel, visualized by
crystal violet dye, compared with size standards, cut out of
the gel and extracted with purification materials included
with the TOPO XL PCR Cloning kit (Invitrogen, Carlsbad,
CA, USA). Long-range PCR products were cloned into a
TOPO XL PCR cloning vector. This system uses a TA cloning
vector and is recommended for inserts of up to 10kb. As per
the manufacturer’s instructions, electro-competent cells
(from the same kit) were transformed by the vector, plated
in the presence of antibiotic and incubated. Altogether, 10
clones from each plate were picked and cultured in a 96-well
format.
Template preparation
Diluted cultures were transferred to a denaturing buffer that
was part of the TempliPhi DNA Sequencing Template
Amplification kit (GE Healthcare/Amersham Biosciences,
Piscataway, NJ, USA). This buffer causes the release of
plasmid DNA but not bacterial DNA. Cultures were heated,
cooled, spun, and transferred to fresh plates containing the
TempliPhi enzyme and other components. This mixture was
incubated at 301C for 18h to promote amplification of the
plasmid templates. These products were then spun and
heated to 651C to destroy the enzyme.
DNA sequencing
Plasmid templates were used in DNA sequencing reactions
using the Big Dye, version 3.1 sequencing kit (Applied
Biosystems, Foster City, CA, USA). For each reaction, an
appropriate sequencing primer (Supplementary Table S1)
was used that was designed to anneal to a unique location of
the template. Cycle sequencing was carried out with an
annealing temperature of 501C, an elongation temperature
of 601C and a denaturation temperature of 961C, for a total
of 30 cycles. Sequencing reaction products were run on an
ABI 3730XL DNA sequencer with a 50-cm capillary array
using standard run mode.
Sequencing data analysis
A proprietary sequencing analysis program called ‘Agent’
(developed by Celera, Alameda, CA, USA) was used to align
sequencing reads to the appropriate reference sequence, and
produce ‘contigs’ associated with each clone. The system
provides estimated quality scores for all bases for which
there is any variation for any of the samples. The sequencing
report for each sample was analyzed for the presence of SNPs
that were correlated in one haplotype pattern for one subset
of clones and in a different haplotype pattern for the
remaining clones. A reference file for the region of interest
was prepared by listing the known variations for that region
publicly available from NCBI dbSNP. A genotype file for the
region of interest was created by searching each subject’s
haplotype report for all variations between the known
reference sequence and the consensus haplotype sequences.
Estimate of length-read error
The magnitude of the length-reading error for the poly-T
variants (for example, rs10524523) was estimated by
examining the observed lengths from the 10 clones that
were prepared for samples that had a single haplotype. For a
typical sample with short poly-T length of 16, the s.d. for the
10 clones was 0.97. For a typical sample with longer poly-T
length, for example, 27, the s.d. was 1.58.
Phylogenetic analysis
Phylogenetic analysis was conducted according to the steps
outlined in Supplementary Figure S1. A multiple sequence
alignment of the sequences was performed using
the ClustalW2 (version 2.0.10, European Bioinformatics
Institute (EBI), Hinxton, UK; http://www.ebi.ac.uk/Tools/
clustalw2/index.html) program using default parameters.
Manual adjustment of the alignments was completed using
Genedoc (version 2.7.000, National Resource for Biomedical
Supercomputing (NRBSC), Pittsburgh, PA, USA; http://
www.nrbsc.org/gfx/genedoc/index.html). Phylogenetic trees
were constructed using Bayesian, maximum likelihood
and distance-based reconstructions. The phylogenetic tree
construction software used was Paup* (version 4.0b10,
Sinauer Associates, Sunderland, MA, USA; http://paup.csit.
fsu.edu), ClustalW2 (neighbor-joining methods, version
2.0.10, European Bioinformatics Institute (EBI), Hinxton,
UK; http://www.ebi.ac.uk/Tools/clustalw2/index.html) and
MrBayes (version 3.1.2, Florida State University, Tallahassee,
FL; http://mrbayes.csit.fsu.edu/index.php).
Tree-bisection and reconnection branch swapping were
used in all methods. The best fitting model of sequence
evolution was estimated using the Modeltest program
(version 3.7, University of Vigo, Spain; http://darwin.
uvigo.es/software/modeltest.html), which provided estimates
for the following key determinants: rate matrix, shape of the
gamma distribution and proportion of invariant sites.
Bootstrap analysis was performed using 1000 replicates to
determine statistical support for specific tree morphology.
Haplotype networks were also constructed from the
sequence data using the program TCS (version 1.21
33,
University of Vigo, Spain; http://darwin.uvigo.es/software/
tcs.html) to compare the phylogenetic trees to cladograms
estimated using statistical parsimony. The phylogenetic
trees and haplotype networks were constructed twice, with
gaps treated as missing data for the first instance and as a
fifth character for the second instance. Nucleotide diversity
in the region of interest was calculated using DnaSP (version
5.00.02
34, University of Barcelona, Spain; http://www.ub.
edu/dnasp).
After construction of the phylogenetic trees, the haplo-
type network and completion of the analysis of nucleotide
diversity in the region of interest, the results from the
TOMM40 and age of onset of AD
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consensus tree. Groups of sequences sharing a recent disease
mutation were presumed to segregate more closely on the
phylogenetic tree; however, sporadic cases due to pheno-
copies, dominance and epistasis can introduce noise into
the phenotype–haplotype relationship.
35 This phylogenetic
analysis focused on a high-level aggregation of clades to
minimize these effects. The clades determined at the first
split in the phylogenetic tree were used to test the
hypothesis that TOMM40 subject haplotypes from clade ‘B’
were associated with the onset of AD at a later age than
subject haplotypes from clade ‘A’ (each subject contributed
two haplotypes to the AD age of onset association
signal). The number of tests of association that are
performed using this approach was orders of magnitude less
than that in typical GWAS, as the phylogenetic analysis
identified categories of evolutionarily related subject haplo-
types. If the tests of association confirmed that the different
clades classified the subject-haplotype data by age of onset,
further statistical analysis was carried out to identify the
variants that separated the sequences into each clade.
Effectively, this analysis assessed the significance of each
variant as a factor that influences age of onset using a series
of one degree of freedom tests guided by the tree structure.
The phylogenetic analyses were conducted using SNP and
insertion/deletion polymorphisms. The statistical tests of
association were adjusted with a Bonferroni correction for
the number of polymorphic sites included in the analysis.
Statistical analyses
Haplotype reports from the Polymorphic analysis software
and reports from DnaSP software (version 5.00.02
34) were
used for subsequent statistical analyses. We analyzed
individual TOMM40 SNP variants, TOMM40 haplotypes
and length of poly-T repeats for association with LOAD risk
for the AS cohort and LOAD age of onset for the DS cohort.
Differences in the proportions of specific TOMM40 alleles
associated with each APOE allele or APOE genotype were
compared using Fisher’s exact test (two-tailed). Starting with
30 parsimony-informative sites and a¼0.05, a Bonferroni
correction for the significance of a specific allelic association
would require a P-value of 0.001. Odds ratios (ORs) were
calculated as the (number of minor alleles in cases/number
of minor alleles in controls)/(number of major alleles in
cases/number of major alleles in controls) and reported
with 95% confidence interval. Means for defined LOAD age
of onset groups were compared by t-tests (two-tailed). A
standard F-test on group variances was performed to
determine whether the t-test was calculated assuming
equal or unequal variances. Statistical analysis was com-
pleted using JMP software (version 8, SAS Institute, Cary,
NC, USA).
Results
Molecular evolutionary analysis of the TOMM40-APOE locus
In an ES, 23kb of DNA containing the TOMM40 and APOE
genes (R1 in Figure 1a) was amplified and sequenced for 83
LOAD cases and 67 age-matched controls, and included
subjects with APOE e3/3, e3/4 and e4/4 genotypes (no e2
alleles) (details of the ES cohort are given in Li et al.
6). The
23-kb region is part of an extended region of LD containing
APOE
17,18 and was selected because it fully contained both
the TOMM40 and APOE genes plus almost 3kb of flanking
sequencing on either side and because of earlier reports that
the TOMM40 gene may be involved in LOAD pathogen-
esis.
6,16 To accomplish sequencing, the 23-kb genomic
region was divided into three B10-kb overlapping segments
(Supplementary Figure S2). Molecular evolutionary analyses
of the three 10-kb regions included phylogenetic recon-
struction, statistical parsimony, haplotype networks and
polynucleotide repeat analysis. Of the three segments, only
one (R2, Figure 1a) supported a phylogenetic tree structure
that had high bootstrap support. The R2 segment encodes
TOMM40 exons 6–10 (Figure 1b). The phylogenetic topology
of the R2 segment had three notable characteristics. First,
the phylogenetic tree was divided into two major clades
(termed A and B) with strong bootstrap support (98%, 1000
replicates). This is an unusually large distinction for the
human intraspecific data. Second, phase resolution of
haplotypes of TOMM40 polymorphisms in R2 with the
linked APOE e4o re3 allele revealed a highly significant
difference in the distribution of the APOE alleles and
genotypes and TOMM40 haplotypes between clades A and
B on the tree. Both clades contained subjects with the e3/3
genotype, but 98% of all clade B TOMM40 haplotypes
occurred in cis to the APOE e3 allele (P¼2.0 10
 24, n¼300,
Fisher’s exact test, two-tailed) (Figure 2). Third, the
TOMM40-APOE genomic region contained a large number
of polynucleotide repeats; however, the repeats that were
polymorphic in length were concentrated in intron 6 of
TOMM40, which is included in the R2 region. Taken
together, these data suggested that this 10-Kb R2 region of
TOMM40 was functionally significant and that these
TOMM40-APOE haplotypes could account for the robust
genetic association of this high LD region.
E10 E9 E8 E7 E6 P
Figure 1 Schematic overview of the TOMM40-APOE locus. (a)
Genomic locations of the TOMM40 and APOE genes on chromosome
19 between 50084480 and 50107480bp. The regions subjected to
primary sequencing and phylogenetic analysis for the exploratory (R1)
(23kb) and confirmatory (R2) (10kb) studies are highlighted on the
genomic map (NCBI Build 36.3). (b) Distribution of SNP and insertion/
deletion polymorphisms are shown on the gene structure of TOMM40
covered in the region that was subjected to primary sequencing. The
region covers exons 6–10 and all associated intronic regions. The
variable poly-T repeat (rs10524523) that is significantly associated with
LOAD age of onset is depicted with the square labeled ‘P’.
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APOE e3-specific inheritance of TOMM40 haplotypes from
clade B, the variable-length polynucleotide repeats and the
identity of the clade-specific polymorphisms that were
observed in the ES were all confirmed in a second
independent LOAD case–control cohort. The AS cohort
was comprised of AD cases (n¼74) and controls (n¼31)
with APOE genotypes e2/3, e2/4, e3/3, e3/4 and e4/4, and the
subjects were ascertained at the Arizona Alzheimer’s Disease
Core Center. The association between the two clades, disease
risk and age of disease onset was explored in the AS cohort
that had a broader spectrum of ages of onset than the ES. A
third cohort, the DS, was assembled at the Duke Bryan
Alzheimer’s Disease Research Center and comprised 34
clinically well-characterized APOE e3/4 LOAD patients,
many of whom had AD confirmed by autopsy on death,
and 33 age-matched controls. Table 1 summarizes the
characteristics of the three cohorts.
Reconstruction of the evolutionary history of the AS
cohort revealed a highly similar phylogenetic tree to that
seen in the ES, with strong bootstrap support (97%, 1000
replicates) for the separation of clades A and B. APOE e4/4
subjects occurred only in clade A, whereas the remaining
APOE genotypes were distributed between clades A and B
(Supplementary Figure S3). Examination of the distribution
of the few APOE e2/4 subjects on the phylogenetic tree
suggested that APOE e2-TOMM40 haplotypes share a similar
evolutionary history with APOE e3-TOMM40 haplotypes. To
verify the phylogenetic structure using a separate method,
and to ensure that recombination within the genetic
interval did not confound the phylogenetic tree structure,
haplotype networks were also constructed using statistical
parsimony (TCS version 1.21
33). The major subject-haplo-
type clusters derived from the two methods (maximum
parsimony and TCS) were congruent.
Association of the rs10524523 poly-T polymorphism with LOAD
risk and age of onset
Mapping the polymorphisms that distinguished the two
major clades of the phylogenetic tree derived for the AS
cohort showed that a poly-T variant, rs10524523, located in
intron 6 of TOMM40 was a key variant that separated the
two clades and, therefore, the two groups of APOE e3
haplotypes. For APOE e4/4 subjects, the variant was
relatively long with a narrow, unimodal distribution of
lengths (21–30 T residues, mean¼26.78, s.d.¼2.60, n¼32),
whereas for APOE e3/3 subjects, a bimodal distribution of
lengths was evident with peaks at 15.17 (s.d.¼0.85, n¼36)
and 33.15 (s.d.¼2.09, n¼55) T residues (Figure 3a). Two
APOE e4/4 AD patients, each having a short poly-T allele
(length 15) that mapped to clade B on the phylogenetic tree,
were identified. These two patients had a later age of AD
onset (78 years) than would be expected, on average, for
individuals possessing two APOE e4 alleles. Histograms of
the rs10524523 length distributions and allele frequencies
for control subjects (that is, not representative of the general
population) from the ES cohort are also provided in
Supplementary Figure S4.
There was a significant association between length
category of the rs10524523 poly-T polymorphism and age
of LOAD onset for the DS cohort of APOE e3/4 subjects, for
whom disease-onset data were available. Longer poly-T
alleles (X27 T residues) were significantly associated
with the onset of disease at a much younger age than
shorter poly-T alleles (70.5 years±1.2 versus 77.6 years±
2.1, P¼0.02, n¼34). This polymorphism, therefore,
Figure 2 Schematic of APOE allele and genotype frequencies associated with the major clades for the phylogenetic tree constructed for the
TOMM40 R2 region (Figure 1) for the ES cohort. The percentage of each APOE allele that is present in clades A and B is indicated (column 2). The
APOE genotypes that are represented in each clade are also given (column 3). n¼300 subject haplotypes.
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who carried a single APOE e3 allele independent of carriage
of a single e4 allele. Three other poly-T length polymorph-
isms located in intron 6 (rs34896370, rs56290633 and
rs10602329) also distinguished clades A and B, but these
polymorphisms were not associated with a statistically
significant difference in age of disease onset.
Longer poly-T lengths (T X27) segregated almost exclu-
sively into clade A, the higher disease risk clade, in the AS
cohort (P¼7.6 10
 46, n¼210, Fisher’s exact test, two-
tailed). The distributions of poly-T lengths linked to specific
APOE alleles in subjects from the ES cohort are shown in
Figure 3b, confirming the APOE allele-specific distribution
of poly-T lengths for the ES and AS cohorts. Case–control
ratios for rs10524523 poly-T lengths for the AS cohort are
provided in Supplementary Table S2.
TOMM40 haplotypes and variants associated with LOAD
AD cases more frequently possessed clade A haplotypes than
clade B haplotypes for all study cohorts (for example, for the
AS cohort, OR¼1.44, 95% confidence interval¼0.76–2.70).
APOE e3/4 heterozygotes in the AS cohort (n¼36) were
analyzed to estimate disease risk associated with clade A
haplotypes while controlling for the effect of APOE e4. There
was a trend to higher incidence of LOAD for the subset that
was homozygous for TOMM40 clade A haplotypes relative to
the subset that was heterozygous for clade A and clade B
haplotypes (OR¼1.36, 95% confidence interval¼0.40–
4.61), and thus it is possible that other variants in TOMM40
that define clade A, in addition to rs10524523, confer APOE
e4-independent risk of LOAD.
Analysis of the AS cohort sequence data identified 39
polymorphic sites, including the poly-T sites, in the
TOMM40 10-kb R2 region. In total, 10 SNPs occurred
exclusively in the context of APOE e3( P¼6.07 10
 50,
n¼210, Fisher’s exact test, two-tailed) and were
never observed in APOE e4/4 homozygous subjects
(n¼16). Figure 4 shows 16 SNPs that distinguish TOMM40
clades A and B for the APOE e3/3 subjects from the AS
cohort. These polymorphisms were tested individually and
Figure 3 Distributions of the rs10524523 variable-length polymorphism for the AS (n¼210 subject haplotypes) and ES (n¼300 subject
haplotypes) cohorts. (a) Histograms of rs10524523 length stratified by APOE genotype for the AS cohort. (b) Histograms of rs10524523 poly-T
lengths and allele frequencies linked to specific APOE alleles for the ES cohort.
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tary Table S3). The ORs for disease risk for each clade B allele,
in all cases the minor allele, suggested that the clade B alleles
are protective of AD risk in the AS cohort, although in each
case the association narrowly missed significance. However,
the minor alleles of four of the SNPs (rs8106922, rs1160985,
rs760136 and rs741780) that distinguish TOMM40 clade B
were assayed previously in four published LOAD case–
control GWAS and were found to be significantly protective
of disease risk (OR o1 in each case), which is consistent with
the trend observed in our smaller study.
8,11,15,17
Discussion
Our discovery of a variable-length sequence repeat poly-
morphism associated with LOAD age of onset adds to the list
of previous examples in which the sequence repeat length
affects disease risk or disease penetrance. For example,
unstable trinucleotide repeats are known to cause or
contribute to risk of at least 14 neurological diseases.
36 For
Huntington’s disease, chromosomes containing short (o36)
polyglutamine (poly-CAG) repeats are benign; however, an
increase of only 2–3 repeats is associated with increased
disease risk.
37 Repeat length is also inversely correlated
with the age of onset of Huntington’s disease.
38 Common
poly-T polymorphisms and TG-repeats in the CFTR gene
have been shown to have a role in the development of cystic
fibrosis-related diseases.
39 The IVS8 poly-T alleles located in
the splicing acceptor site of intron 8 of CFTR, for example,
variously affect skipping of exon 9 and the production of
nonfunctional protein.
40 Whether different poly-T lengths
at TOMM40 rs10524523 also result in exon skipping is
unknown. Alternatively, it is possible that the rs10524523
polymorphism, alone or in conjunction with other SNPs in
TOMM40, acts at a distance to affect transcription of APOE.
It has previously been shown that polymorphisms in
TOMM40 affect levels of apoE protein in the cerebrospinal
fluid of non-demented individuals and in the hippocampus
of AD patients.
41,42 Finally, as there is evidence of inter-
action between apoE protein and the mitochondria,
28 it
could be envisioned that the TOMM40 polymorphisms
affect the production of specific Tom40 isoforms that
interact in a complex way with apoE isoforms encoded by
APOE e2, e3o re4.
It is highly probable that African, Asian, Caucasian and
other ethnic groups have very different phylogenetic
patterns in the APOE-TOMM40 region. This may affect the
clinical usefulness, for non-Caucasians, of the data pre-
sented here and this could be especially problematic in the
pharmacogenetic interpretation of global clinical trials. This
factor must be considered when large Phase III trials do not
confirm the efficacy found in original Phase II experiments
based solely on Caucasians. As an example, it has been
established that treatment of non-small cell lung carcinoma
with gefitinib is particularly efficacious for Asian patients
relative to Caucasian patients and this is related to
mutations of the drug target that occur frequently in
Asians.
43,44 In addition, there are descriptions in the
literature of ethnic-specific adverse events.
45,46 The linkage
of potentially contributing loci, which may vary according
to the evolutionary history of different ethnicities, should
be considered carefully when designing large, global clinical
trials in which pharmacogenetics will be applied. There are
certainly data sets where this could be tested, as it may be a
contributing factor to the recent drug development failures
in which clinical trials had different ethnic mixes.
47–49
We conclude that longer poly-T tracts at rs10524523 are
significantly correlated with earlier age of onset of LOAD.
The length of this variant on APOE e4 chromosomes is
relatively homogeneous and relatively long on APOE e4
chromosomes, whereas there are two distinct groups of
poly-T lengths linked to APOE e3. APOE e2 chromosomes
also seem to carry variable-length poly-T repeats similar to
e3 chromosomes, but further investigation is needed to
verify this preliminary finding and to determine whether
the poly-T repeat affects the very late age of disease onset for
carriers of APOE e2. Of all the variants that distinguished the
Figure 4 Phylogenetic tree showing separation of SNP variants that distinguish clades A and B. Separation of the two main branches has strong
bootstrap support (973 of 1000). These SNPs distinguish the two clades for both the ES and AS cohorts.
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describes age of LOAD onset. However, at this time, we
cannot exclude the possibility that other variants that occur
in haplotypes with rs10524523, or in the APOE LD region
which we did not sequence are actually causative. The
distribution of rs10524523 of length alleles into major
clades of the phylogenetic tree suggests that this poly-
morphism is inherited faithfully in haplotypes with specific
alleles of APOE (Figure 5) and do not represent dynamic
mutations as observed in other neurological diseases.
Although it is possible that there are other variants that
influence the age of onset of LOAD for individuals who are
not homozygous for APOE e4, the length of the poly-T
polymorphism in TOMM40 intron 6 seems to be the most
powerful genetic predictor in this linkage region, and should
be validated in prospectively collected series of normal
subjects being followed for the development of LOAD. These
data also suggest that APOE genotype-stratified age of onset
curves
5,6 are, in reality, families of curves with each curve
reflecting a specific interaction of linked polymorphisms in
APOE and TOMM40. After validation, these data will add
resolution to the prediction of age of LOAD onset, within an
8-year window, for Caucasian individuals 460 years of age.
A prospective, population-based study to validate the
association of APOE genotypes and TOMM40 haplotypes or
rs10524523 with age of disease onset, and to determine the
utility of these alleles for prediction of age of onset, is
currently being planned. This study will be a prospective,
5-year population-based study conducted in several ethnic
groups, and will be combined with a prevention or delay of
disease onset drug trial for individuals whose genetics and
age would predict that they are at high risk of developing
LOAD within 5–7 years. Population-based studies should
also be conducted in several ethnic groups for whom the
phylogenetic structure of the TOMM40-APOE region is
known to further our understanding of the role of the
poly-T repeat and other nearby polymorphisms in LOAD.
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